Santhera Pharmaceuticals Reports Strong H1 2025 Growth

Santhera Pharmaceuticals Holding Ag ( (SPHDF) ) has released its Q2 earnings. Here is a breakdown of the information Santhera Pharmaceuticals Holding Ag presented to its investors.

Santhera Pharmaceuticals Holding AG, a Swiss specialty pharmaceutical company, focuses on developing and commercializing treatments for neuromuscular and pulmonary diseases, with a particular emphasis on rare conditions with high unmet needs. In its half-year 2025 financial report, Santhera highlighted a significant 70% increase in total revenue, reaching CHF 24 million, driven by the strong performance of AGAMREE® for Duchenne muscular dystrophy. The company also reported a 76% rise in product sales, primarily from Germany, Austria, and the UK, and a substantial increase in royalties from licensing partners in the U.S. and China.

Key financial metrics include an operating loss of CHF 35.4 million, attributed to a USD 25 million sales milestone payment, and a decrease in cash and cash equivalents to CHF 18.4 million. Santhera has secured CHF 20 million in additional growth capital to support its global expansion efforts. The company continues to advance its global rollout of AGAMREE, with new distribution agreements in several countries and ongoing pricing and reimbursement discussions in Europe.

Santhera’s strategic focus remains on maximizing the DMD opportunity with AGAMREE, while also exploring potential portfolio expansions through licensing and distribution agreements. The company anticipates exceeding its full-year 2025 revenue guidance and maintains its cash-flow break-even target for mid-2026.

Looking ahead, Santhera is optimistic about its continued growth, driven by strong demand for AGAMREE and ongoing global expansion efforts. The management remains committed to achieving its financial targets and expanding patient access to its treatments worldwide.